NCT04213664

Brief Summary

PubMed, ScienceDirect, Cochrane Database of Systematic Reviews will be used to search for articles published from January 1965 to July 2019 using the key words "renal cancer", "lymphocyte to monocyte ratio" and "prognosis". No restrictions to date, language, or article type will be applied. Cohort or observational studies in patients with non-metastatic renal cell carcinoma histopathologically confirmed, with hazard ratios (HR) and corresponding 95% confidence intervals (CI) that assessed association between LMR and overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and disease-free survival (DFS) will be analyzed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
4,666

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 25, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 30, 2019

Completed
1 day until next milestone

Study Start

First participant enrolled

December 31, 2019

Completed
2 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2020

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2020

Completed
Last Updated

January 2, 2020

Status Verified

December 1, 2019

Enrollment Period

2 days

First QC Date

December 25, 2019

Last Update Submit

December 31, 2019

Conditions

Renal Cell CarcinomaProgressionLymphocyte DisorderMonocytosisLocal Disease

Keywords

renal cancerlymphocyte to monocyte rationon metastaticprognosismeta-analysisnephrectomy

Outcome Measures

Primary Outcomes (1)

  • Preoperative Lymphocyte to Monocyte Ratio ( LMR) is a prognostic factor in non-metastatic renal cell carcinoma

    Preoperative Lymphocyte to Monocyte Ratio ( LMR) is a prognostic factor patients who underwent nephrectomy for non-metastatic renal cell carcinoma

    Preoperative Lymphocyte to Monocyte Ratio ( LMR) will be determined one month before surgical treatment. Follow-up: through study completion, an average of 5 years.

Study Arms (1)

non-metastatic renal cell carcinoma

Pretreatment lymphocyte to monocyte ratio in non-metastatic patients with renal cell

Other: prognosis

Interventions

prognosisOTHER

cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival

non-metastatic renal cell carcinoma

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with non-metastatic renal cell carcinoma who underwent radical or partial nephrectomy

You may qualify if:

  • PubMed, ScienceDirect, Cochrane Database of Systematic Reviews will be used to search for articles published from January 1965 to July 2019 using the key words "renal cancer", "lymphocyte to monocyte ratio" and "prognosis".
  • No restrictions to date or language will be applied.
  • Cohort or observational studies in patients with non-metastatic renal cell carcinoma who underwent radical or partial nephrectomy, with hazard ratios (HR) and corresponding 95% confidence intervals (CI) that assessed association between LMR and overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and disease-free survival (DFS) will be analyzed.
  • There were no restrictions about gender and ethnicity.

You may not qualify if:

  • Reviews, case reports, conference abstracts, letters, animal or cell studies.
  • Patients were diagnosed non-metastatic renal cell carcinoma, but without standard treatments (Ablative therapy).
  • Preoperative inflammatory markers were not measured.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Corporacion Parc Tauli

Sabadell, Outside U.S./Canada, 08208, Spain

RECRUITING

Related Publications (7)

  • Li J, Cheng Y, Ji Z. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019 Jan;98(2):e14091. doi: 10.1097/MD.0000000000014091.

    PMID: 30633220BACKGROUND

  • Grimes N, Tyson M, Hannan C, Mulholland C. A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent. Clin Genitourin Cancer. 2016 Aug;14(4):271-6. doi: 10.1016/j.clgc.2016.01.006. Epub 2016 Jan 22.

    PMID: 26949171BACKGROUND

  • Wang X, Su S, Guo Y. The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017 Sep 20;8(48):84506-84514. doi: 10.18632/oncotarget.21108. eCollection 2017 Oct 13.

    PMID: 29137443BACKGROUND

  • Hutterer GC, Stoeckigt C, Stojakovic T, Jesche J, Eberhard K, Pummer K, Zigeuner R, Pichler M. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol. 2014 Oct;32(7):1041-8. doi: 10.1016/j.urolonc.2014.04.001. Epub 2014 Jul 11.

    PMID: 25027686RESULT

  • Chang Y, Fu Q, Xu L, Zhou L, Liu Z, Yang Y, Lin Z, Xu J. Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma. Tumour Biol. 2016 Apr;37(4):4613-20. doi: 10.1007/s13277-015-4300-7. Epub 2015 Oct 27.

    PMID: 26508025RESULT

  • Xia WK, Wu X, Yu TH, Wu Y, Yao XJ, Hu H. Prognostic significance of lymphocyte-to-monocyte ratio and CRP in patients with nonmetastatic clear cell renal cell carcinoma: a retrospective multicenter analysis. Onco Targets Ther. 2016 May 9;9:2759-67. doi: 10.2147/OTT.S101458. eCollection 2016.

    PMID: 27274272RESULT

  • Garcia-Rojo D, Prera A, Munoz-Rodriguez J, Oliva JC, Dominguez A, Prats J. Prognostic value of lymphocyte-to-monocyte ratio previously determined to surgery in patients with non-metastatic renal cell carcinoma: A systematic review and a prisma-compliant meta-analysis. Medicine (Baltimore). 2021 Jan 22;100(3):e24152. doi: 10.1097/MD.0000000000024152.

    PMID: 33546029DERIVED

MeSH Terms

Conditions

Carcinoma, Renal CellDisease ProgressionKidney Neoplasms

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Garcia-Rojo

    Corporacion Parc Tauli.Sabadell. Spain

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Garcia-Rojo

CONTACT

0034661179045dgarcia@tauli.cat

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 25, 2019

First Posted

December 30, 2019

Study Start

December 31, 2019

Primary Completion

January 2, 2020

Study Completion

January 31, 2020

Last Updated

January 2, 2020

Record last verified: 2019-12

Locations

ES(1)